| Mesenchymal stem cell research | Lifetime | 44 | CN 6 | 99.62 |
| Immune cells in cancer | Lifetime | 95 | CN 4 | 99.32 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 246 | CN 8 | 99.40 |
| Long-Term Effects of COVID-19 | Lifetime | 227 | CN 15 | 97.91 |
| Immunotherapy and Immune Responses | Lifetime | 552 | CN 12 | 99.10 |
| Immune Cell Function and Interaction | Lifetime | 723 | CN 17 | 99.07 |
| Cancer Cells and Metastasis | Lifetime | 347 | CN 15 | 98.43 |
| CAR-T cell therapy research | Lifetime | 482 | CN 9 | 98.60 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 806 | CN 46 | 98.06 |
| Epigenetics and DNA Methylation | Lifetime | 865 | CN 79 | 98.08 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 403 | CN 17 | 97.81 |
| Extracellular vesicles in disease | Lifetime | 443 | CN 133 | 96.54 |
| Cancer-related Molecular Pathways | Lifetime | 714 | CN 31 | 97.65 |
| Chemokine receptors and signaling | Lifetime | 241 | CN 5 | 96.30 |
| Cancer Research and Treatments | Lifetime | 896 | CN 55 | 96.05 |
| Inflammasome and immune disorders | Lifetime | 569 | CN 56 | 95.25 |
| Berberine and alkaloids research | Lifetime | 165 | CN 54 | 93.75 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 490 | CN 73 | 92.36 |
| Medicinal Plant Pharmacodynamics Research | Lifetime | 162 | CN 108 | 89.28 |
| NF-κB Signaling Pathways | Lifetime | 937 | CN 70 | 92.89 |
| IL-33, ST2, and ILC Pathways | Lifetime | 947 | CN 42 | 92.36 |
| Phagocytosis and Immune Regulation | Lifetime | 767 | CN 53 | 90.69 |
| Immune responses and vaccinations | Lifetime | 898 | CN 38 | 81.01 |
| Natural Compounds in Disease Treatment | Lifetime | 572 | CN 293 | 71.08 |
| Mechanisms of cancer metastasis | Lifetime | 962 | CN 220 | 58.31 |
| Immune Cell Function and Interaction | 2021-2025 | 17 | CN 4 | 99.49 |
| Mesenchymal stem cell research | 2021-2025 | 11 | CN 7 | 98.91 |
| Immunotherapy and Immune Responses | 2021-2025 | 40 | CN 9 | 99.30 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 139 | CN 20 | 99.48 |
| Epigenetics and DNA Methylation | 2021-2025 | 79 | CN 37 | 98.08 |
| Immune cells in cancer | 2021-2025 | 62 | CN 36 | 98.24 |
| CAR-T cell therapy research | 2021-2025 | 219 | CN 13 | 98.45 |
| T-cell and B-cell Immunology | 2021-2025 | 118 | CN 11 | 95.90 |
| Cancer Genomics and Diagnostics | 2021-2025 | 613 | CN 42 | 96.16 |
| RNA modifications and cancer | 2021-2025 | 671 | CN 456 | 95.04 |
| Cancer Cells and Metastasis | 2021-2025 | 282 | CN 60 | 91.93 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 425 | CN 183 | 91.37 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 182 | CN 11 | 90.58 |
| Ferroptosis and cancer prognosis | 2021-2025 | 940 | CN 797 | 89.83 |
| Inflammasome and immune disorders | 2021-2025 | 425 | CN 199 | 88.95 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 987 | CN 166 | 88.70 |
| Cell Adhesion Molecules Research | 2021-2025 | 259 | CN 29 | 84.46 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 511 | CN 312 | 85.00 |
| Telomeres, Telomerase, and Senescence | 2021-2025 | 201 | CN 17 | 84.43 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 446 | CN 183 | 81.90 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 806 | CN 161 | 77.86 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 215 | CN 51 | 77.68 |
| Bone Metabolism and Diseases | 2021-2025 | 569 | CN 263 | 77.17 |
| melanin and skin pigmentation | 2021-2025 | 527 | CN 140 | 76.56 |
| Cancer-related Molecular Pathways | 2021-2025 | 809 | CN 172 | 74.19 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 983 | CN 293 | 73.65 |
| Liver physiology and pathology | 2021-2025 | 692 | CN 305 | 71.74 |
| RNA regulation and disease | 2021-2025 | 987 | CN 235 | 68.16 |
| Adenosine and Purinergic Signaling | 2021-2025 | 601 | CN 146 | 69.98 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 664 | CN 186 | 46.62 |
| Kruppel-like factors research | 2021-2025 | 958 | CN 379 | 45.43 |
